Orion Oyj is a globally operating pharmaceutical company based in Finland that focuses on the research, development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). The company's business model spans the entire pharmaceutical value chain, from proprietary drug discovery to the production of generic medications and self-care products. Orion's research and development efforts are primarily concentrated on three core therapeutic areas: oncology, neurological disorders, and respiratory diseases.
A significant driver of Orion's revenue is its Innovative Medicines division, which includes proprietary drugs such as Nubeqa (darolutamide) for prostate cancer, developed and commercialized in partnership with Bayer. The company also generates substantial sales from its Branded Products and Generics divisions, which offer a wide range of off-patent prescription drugs and over-the-counter consumer health products. Additionally, Orion's Animal Health division provides veterinary medicines for both companion and livestock animals, while its Fermion unit manufactures APIs for Orion's own use and for third-party pharmaceutical companies.
Geographically, Finland is Orion's largest single market, where it holds a leading market share. However, the company distributes its products in over 100 countries worldwide. In Europe, Orion operates through its own sales network, while in other global markets, including North America and Asia, it relies on a network of collaboration partners and licensing agreements. All of the company's manufacturing facilities and the majority of its research and development operations are located in Finland.
